論文（英文）

• Hasegawa K, Makuuchi M, Takayama T, Kokudo N, Arii S, Okazaki M, Okita K, Omata M, Kudo M, Kojiro M, Nakanuma Y, Takayasu K, Monden M, Matsuyama Y, and Ikai I for the Liver Cancer Study Group of Japan. Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: A preliminary report of the Japanese nationwide survey. /Journal of Hepatology/ 2008; 49: 589-594.
• Uemura K, Matsuyama Y, and Ohashi Y. A modified conditional power approach for increasing the sample size based on an interim estimate of treatment difference. Japanese Journal of Biometrics 2008; 29: 19-34.
• Tateishi R, Yoshida H, Matsuyama Y, Mine N, Kondo Y, and Omata M. Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review. Hepatology International 2008; 2: 17-30.
• Hasegawa K, Imamura H, Ijichi M, Matsuyama Y, Sano K, Sugawara Y, Kokudo N, and Makuuchi M. Inclusion of tumor markers improves thecorrelation of the Milan criteria with vascular invasion and tumor cell differentiation in patients with hepatocellular carcinoma undergoing liver resection. /Journal of Gastrointestinal Surgery/ 2008; 12(5):858-866.
• Eguchi S, Kanematsu T, Arii S, Okazaki M, Okita K, Omata M, Ikai I, Kudo M, Kojiro M, Makuuchi M, Monden M, Matsuyama Y, Nakanuma Y, Takayasu K for the Liver Cancer Study Group of Japan. Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey. Surgery 2008; 143: 469-475.
• Makuuchi M, Kokudo N, Arii S, Futagawa S, Kaneko S, Kawasaki S, Matsuyama Y, Okazaki M, Okita K, Omata M, Saida Y, Takayama T, and Yamaoka Y. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatology Research 2008 38: 37-51.
• Tanaka Y, Matsuyama Y, and Ohashi Y. for the MEGA Study Group. Estimation of treatment effect adjusting for treatment changes using the intensity score method: an application to a large primary prevention study for coronary events (MEGA study). Statistics in Medicine 2008; 27:1718-1733.
• Takeuchi Y, Ohnishi Y, Matsunaga S, Nakayama H, Uetsuka K. Intracranial meningioma with polygonal granular cell appearance in a Chihuahua. J Vet Med Sci. 2008; 70(5): 529–532.
• Sakamoto J, Hamada C, Yoshida S, Kodaira S, Yasutomi M, Kato T, Oba K, Nakazato H, Saji S, Ohashi Y. An individual patient data meta-analysis of adjuvant therapy with uracil-tegafur (UFT) in patients with curatively resected rectal cancer. Brit J Cancer 2007; 96: 1170-7.
• Kobayashi M, Oba K, Sakamoto J, Kondo K, Nagata N, Okabayashi T. Pharmacokinetic study of paclitaxel of weekly administration dose in advanced or recurrent gastric cancer patients in Japan. Gastric Cancer 2007; 10:52-7.
• Ninomiya M, Kondo K, Matsuo K, Hirabayashi N, Kojima H, Kobayashi M, Kawamura S, Ando T, Musha N, Konno H, Nagata N, Usuki H, Miyashita Y, Oba K, Morita S, Sakamoto J. Multicenter Phase II Trial of Combination Chemotherapy with Weekly Paclitaxel and 5-Fluorouracil for the Treatment of Advanced or Recurrent Gastric Carcinoma. J Chemotherapy 2007; 19:444-50.
• Oba K, Teramukai S, Kobayashi M, Matsui T, Kodera Y, Sakamoto J. Efficacy of Adjuvant Immunochemotherapy with Polysaccharide K for Patients with Curative Resections of Gastric Cancer. Cancer Immunol Immun 2007; 56:905-11.
• Ikai I, Arii S, Okazaki M, Okita K, Omata M, Kojiro M, Takayasu K, Nakanuma Y, Makuuchi M, Matsuyama Y, Monden M, and Kudo M. Report of the 17th nationwide follow-up survey of primary liver cancer in Japan. Hepatology Research 2007; 37(9):676-691.
• Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y, and Makuuchi M. Staging of hepatocellular carcinoma: Assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Annals of Surgery 2007; 245(6):909-922.
• Yoshida M, Matsuyama Y, and Ohashi Y for the MEGA Study Group. Estimation of treatment effect adjusting for dependent censoring using the IPCW method: an application to a large primary prevention study for coronary events (MEGA study). Clinical Trials 2007; 4: 318-328.
• Tanaka S, Matsuyama Y, Shiraki M, Ohashi Y. Estimating the effect of time-varying treatments: Incidence of fractures among postmenopausal Japanese women. Epidemiology 2007; 18: 529-536.
• Nakagami G, Sanada H, Konya C, Kitagawa A, Tadaka E, and Matsuyama Y. Evaluation of a new pressure ulcer preventive dressing containing ceramide 2 with low frictional outer layer. Journal of Advanced Nursing 2007; 59(5): 520-529.
• Shimizu F, Matsuyama Y, Tominaga T, Ohashi Y, and Fujime M. Inadequacy of prostate-specific antigen doubling time estimates calculated using an ultrasensitive assay of prostate-specific antigen for biochemical failure after radical prostatectomy. Urologia Internationalis 2007; 79: 356-360.
• Shimizu F, Tanaka S, Matsuyama Y, Tominaga T, Ohashi Y, and Fujime M. Efficiency of ultrasensitive prostate-specific antigen assay in diagnosing biochemical failure after radical prostatectomy. Japanese Journal of Clinical Oncology 2007; 37: 446-451.
• Minagawa, M, Yamamoto J, Kosuge T, Matsuyama Y, Miyagawa S, and Makuuchi M. Simplified staging system for predicting the prognosis of patients with resectable liver metastasis: Development and Validation. Archives of Surgery 2007; 142(3):269-276.

TOP